Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Schematic presentation <i>M</i>. <i>bovis</i> PG45 5′ nucleotidase and phylogenetic tree of its homologs. by Aga E. Gelgie (17661720)

Subjects:

Oligonucleotides used in this study. by Aga E. Gelgie (17661720)

Subjects:

Data supporting the findings of this study. by Aga E. Gelgie (17661720)

Subjects:

Impact of 5′ nucleotidase disruption on <i>M</i>. <i>bovis</i> growth phenotype in axenic conditions. by Aga E. Gelgie (17661720)

Subjects:

<i>M</i>. <i>bovis</i> 0690::Tn mutant failed to elicit the recruitment of neutrophils into milk spaces. by Aga E. Gelgie (17661720)

Subjects:

Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant. by Aga E. Gelgie (17661720)

Subjects:

Inhibitory effect of 7DHC and BM15766 in HF organoid culture. by Leemon Nikhila (22250736)

Subjects:

Inhibited cholesterol biosynthesis downregulates hair follicle stem cell marker genes in in vitro model system. by Leemon Nikhila (22250736)

Subjects:

7DHC and BM15766 treated mice (C57BL/6; n = 5) failed to regrow the hairs. by Leemon Nikhila (22250736)

Subjects:

Down -regulated expression of HFSC marker genes in PCA. by Leemon Nikhila (22250736)

Subjects:

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Subjects:

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Subjects:

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Subjects:

Mapping of transposon insertions in the selected mutants of <i>M</i>. <i>bovis</i> PG45. by Aga E. Gelgie (17661720)

Subjects:

(A and B) ChIP-qPCR analysis of HSF2 binding to the indicated KSHV genomic regions expressed as % of input in KSHV infected latent (A) and lytic (B) cells. by Lorenza Cutrone (21144285)

Subjects: